Aziyo Biologics Q2 EPS $(0.65) Misses $(0.29) Estimate, Sales $10.30M Miss $12.50M Estimate
Portfolio Pulse from sunil@benzinga.com
Aziyo Biologics reported Q2 losses of $0.65 per share, missing the analyst consensus estimate of $0.29 by 124.14%. The company's quarterly sales were $10.30 million, missing the estimate of $12.50 million by 17.63%. This represents a 5.8% increase in losses and an 18.53% decrease in sales compared to the same period last year.
August 14, 2023 | 8:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aziyo Biologics reported larger than expected losses and lower than expected sales for Q2.
Aziyo Biologics reported larger than expected losses and lower than expected sales for Q2. This could indicate financial instability and may negatively impact investor confidence, potentially leading to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100